IC-ONC Annual Forum - Building Collaboration Among Multidisciplinary Care Teams ​for Early Recognition, Referral, Testing, Treatment and Management ​of Patients with Cancer Receiving Immunotherapy

Course Description:

Together, UVACE, ASCP, SBP, and The Micron Group, as collaborators on IC-ONC activities, will continue to build on their collective experience and expertise to advance knowledge and competence among members of the multidisciplinary cancer care team and advance patient health, to ensure that patients who may be eligible for immunotherapy receive effective, timely, and equitable I-O biomarker testing, treatment, and follow up.

Two 90-minute, previously recorded, credit-bearing tumor boards will feature a multidisciplinary panel of experts discussing complex patient cases in melanoma, NSCLC, bladder, and renal cell cancers, which are all candidates for combination immunotherapy and common in minority populations. Throughout the virtual tumor boards, presenters will weave in health equity concepts to support equitable care for patients who can potentially benefit from immunotherapy therapies for a cancer diagnosis.

As a result of participating in these virtual tumor boards, members of the multidisciplinary cancer and continuity-based health care teams will learn strategies for ensuring that patients who may be eligible for immunotherapy receive effective, timely, and equitable I-O biomarker testing, diagnosis, treatment, and follow up management through ongoing care from their primary and affiliated institutions.

Faculty List

William J. Brady, MD

University of Virginia

Jann Balmer, PhD, RN, FACEHP, FAAN

University of Virginia

Ryanne A. Brown, MD, MBA

Stanford Medicine

Priyanka V. Chablani, MD, MS

University of Pittsburgh Medical Center

Marianne Davies, NP, DNP, MSN, BSN

Yale School of Medicine

Michael E. Devitt, MD

University of Virginia

Elizabeth M. Gaughan, MD

University of Virginia

Tao Huang, BM

University of Michigan Rogel Cancer Center

Lisa A. Kottschade, R.N., C.N.P.

Mayo Clinic College of Medicine and Science

Erin Schenk, MD, PhD

University of Colorado

Rumeal D. Whaley, MD, FACP

Mayo Clinic College of Medicine and Science

Laura Wood, RN, MSN, OCN

Boston Children’s Hospital

Target Audience

The target audience for this program includes all members of the entire multidisciplinary cancer care team, including of pathologists, laboratory professionals (e.g., medical laboratory scientists and laboratory administrators), medical and radiation oncologists, surgeons, advanced practice providers, nurses. Other members of the extended care team including Emergency Medicine, Primary care and hospitalist physicians, PA, APRNS, MSWs (e.g., surgical, emergency medicine teams, primary care, hospitalist etc.), technicians, healthcare administrators will also be included as they address challenges related to immuno-oncology (I-O) biomarker testing, treatment, and collaborative care.

IC-ONC Annual Tumor Board Desired Outcomes

For patients with NSCLC, melanoma, renal cell carcinoma, and bladder cancer: Discuss the basic concepts of immune-based therapy, including immunosurveillance and immunosuppression of the tumor microenvironment. Describe strategies for improving communication and systems-based pathways to foster early detection and management of irAEs that can impact patient outcomes. Update and optimize biomarker testing policies and workflow processes to adhere to evidence- based guidelines. Discuss the value of proactive collaboration across the expanded multidisciplinary care team in the early recognition, referral, testing, treatment, and management. Relate the recommended pan-tumor biomarkers and testing methods with the selection of I-O treatments according to current evidence-based guidelines. Discuss strategies for improving access and equity in I-O tests, therapies and management for under-represented patients with cancer. Advocate an expanded multidisciplinary approach across the care continuum for heightened awareness, recognition, management and referrals of serious and life-threatening irAEs to healthcare clinicians and teams optimizing care for all patients with cancer.

Accreditation and Designation Statement

In support of improving patient care, this activity has been planned and implemented by the American Society for Clinical Pathology, The Society of Black Pathologists, the University of Virginia School of Medicine and School of Nursing is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME ), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC),to provide continuing education for the healthcare team.

The University of Virginia School of Medicine and School of Nursing designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Virginia School of Medicine and School of Nursing awards 1.50 hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™ or ANCC contact hours) to a participant who successfully completes this enduring activity. The University of Virginia School of Medicine and School of Nursing maintains a record of participation for six (6) years.

CE Credit for these enduring materials will be available March 1, 2024 - December 31, 2024. In order to claim CE credit, learners must complete the post course evaluation.

Speakers and Planning Committee Disclosures

The following have disclosed no financial relationship or interest with any proprietary entity producing healthcare goods or services.

• Jann T. Balmer, PhD, RN*
• William Brady, MD*
• Michael E. Devitt, MD
• Ryanne Brown, MD
• Pamela S. Lace, MA*
• Marianne Davies, DNP, RN*
• Tao Huang, MD
• Gretchen Keefer*
• Rumeal Whaley, MD

(*) Designates planning committee members

Priyanka V. Chablani, MD, MS has disclosed consultant/advisory committee/board at Bayer, Exelixis and AVEO Oncology and part- time employment at VA Pittsburgh as part of her UPMC appointment

Elizabeth Gaughan, MD has disclosed industry funded research/investigator at Regeneron

Lisa Kottschade, NP has disclosed a consultant role at Immunocore

Erin Schenk, MD has disclosed a consultant role at AstraZeneca; consultant/advisory committee/board at Harpoon Therapeutics, Janssen, Actinium; advisory committee/board at Thetis Pharmaceuticals, BioAtla, Regeneron, G1 Therapeutics and advisory committee/board, speakers bureau, faculty, peer reviewer at Sanofi/Regeneron

Laura Wood, RN, MSN, OCN has disclosed speakers bureau, faculty/peer reviewer at Aveo, Bristol Myers Squibb, EMD Serono, Exelixis, Merck and Pfizer

Disclosure of faculty financial affiliations

The University of Virginia School of Medicine and School of Nursing as a Joint Accreditation Provider adhere to the ACCME Standards for Integrity and Independence in Accredited Continuing Education, released in December 2020, as well as Commonwealth of Virginia statutes, University of Virginia policies and procedures, and associated federal and private regulations and guidelines. As the accredited provider for this CE/IPCE activity, we are responsible for ensuring that healthcare professionals have access to professional development activities that are based on best practices and scientific integrity that ultimately supports the care of patients and the public.

All individuals involved in the development and delivery of content for an accredited CE/IPCE activity are expected to disclose relevant financial relationships with ineligible companies occurring within the past 24 months (such as grants or research support, employee, consultant, stock holder, member of speakers bureau, etc.). The University of Virginia School of Medicine and School of Nursing employ appropriate mechanisms to resolve potential conflicts of interest and ensure the educational design reflects content validity, scientific rigor and balance for participants. Questions about specific strategies can be directed to the University of Virginia School of Medicine and School of Nursing of the University of Virginia, Charlottesville, Virginia.

The faculty, staff, CE Advisory Committee and planning committee engaged in the development and/or peer review of this CE/IPCE activity in the Joint Accreditation CE Office of the School of Medicine and School of Nursing have no financial affiliations to disclose.

All financial affiliations have been mitigated to ensure independence and integrity in the educational content.

Disclosure of discussion of non-FDA approved uses for pharmaceutical products and/or medical devices

As a Joint Accreditation provider, the University of Virginia School of Medicine and School of Nursing, requires that all faculty presenters identify and disclose any off-label or experimental uses for pharmaceutical and medical device products. It is recommended that each clinician fully review all the available data on new products or procedures prior to clinical use.

Disclaimer Information: CE activities accredited by University of Virginia School of Medicine and School of Nursing are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisional of any kind. Learners are not authorized to copy, modify, reproduce, re-publish, sub-license, sell, upload, broadcast, post, transmit or distribute any of the Course Materials.